Chondroitin sulfate - IBSA
Alternative Names: Chondroitin 4-sulfate - IBSA; Chondroitin 4-sulfate sodium - IBSA; Chondroitin 6-sulfate - IBSA; Chondroitin 6-sulfate sodium - IBSA; Chondroitin sulfate A - IBSA; Chondroitin sulfate A sodium - IBSA; Chondroitin sulfate sodium - IBSA; Chondroitin sulphate - IBSA; Chondrosulf; Condrosulf (IBSA); Condrosulf (Salus Braumapharm)Latest Information Update: 19 Oct 2023
At a glance
- Originator IBSA
- Developer IBSA; Laboratoires Genevrier; Sanova Pharma; SPA
- Class Anti-inflammatories; Antirheumatics; Glycosaminoglycans
- Mechanism of Action Collagen stimulants; Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoarthritis
Most Recent Events
- 05 Oct 2023 IBSA withdraws a phase III MOTION trial for Osteoarthritis (In adults, In the elderly) (PO), prior to enrolment (NCT05632783)
- 01 Dec 2022 IBSA plans a phase III trial for Osteoarthritis in April 2023 (PO, Tablet) (NCT05632783)
- 01 Mar 2022 Discontinued - Phase-III for Osteoarthritis in Poland, Belgium (PO)